ABGX Abgenix (MM)

Abgenix to Present at Needham & Company's Fourth Annual Biotechnology Conference FREMONT, Calif., May 20 /PRNewswire-FirstCall/ -- Abgenix, Inc. (NASDAQ:ABGX) today announced that it will present at Needham & Company's Fourth Annual Biotechnology Conference on Thursday, May 26, 2005 at 10:30 a.m. PT / 1:30 p.m. ET. The presentation will be webcast live and may be accessed by visiting the Abgenix website at http://www.abgenix.com/. A replay of the webcast will also be available on the company's website until Thursday, June 9, 2005. Dr. Gisela Schwab, chief medical officer of Abgenix, will provide an overview of the company's antibody development activities. About Abgenix Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the- art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through its own development efforts and the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at http://www.abgenix.com/. DATASOURCE: Abgenix, Inc. CONTACT: Aisha Santiago, Corporate Communications & Investor Relations of Abgenix, Inc., +1-510-284-6858 or +1-510-284-6605; or E. Blair Schoeb, Corporate Communications, +1-212-923-6737, for Abgenix, Inc. Web site: http://www.abgenix.com/

Copyright